Telmisartan Tablets
ID: SPE2E2-24-R-0015Type: Solicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/cf2caa9d521c4d05919c53335b4aa418/view
Timeline
    Description

    The Defense Logistics Agency (DLA) is soliciting proposals for the procurement of Telmisartan Tablets, a pharmaceutical product essential for various medical applications, under Solicitation No. SPE2D2-24-R-0015. The contract aims to secure a reliable supply of these tablets in multiple dosages over several years, emphasizing compliance with federal regulations, including the necessity for a Subcontracting Plan for large businesses and adherence to various Federal Acquisition Regulation (FAR) clauses. Interested contractors should note that the submission deadline has been extended to February 28, 2025, at 3:00 PM EST, and are encouraged to contact Courtney Hunter-Stangler at Courtney.Hunter-Stangler@dla.mil or Jason Wray at jason.wray@dla.mil for further inquiries.

    Point(s) of Contact
    Courtney Hunter-Stangler
    (215) 737-6845
    Courtney.Hunter-Stangler@dla.mil
    Jason Wray
    (215) 737-0614
    jason.wray@dla.mil
    Files
    Title
    Posted
    SF30_SPE2D224R00150001.PDF
    The document serves as an amendment to a federal solicitation for contract SPE2D224R0015. The main purpose is to inform stakeholders that the solicitation closing date has been extended to February 21, 2025, at 3:00 PM EST. It outlines the administrative processes related to this change, indicating that all other terms and conditions remain unchanged, reinforcing the continuity of the contract’s provisions. Offers submitted prior to the new deadline must acknowledge this amendment to avoid rejection. The amendment ensures clarity and compliance with federal guidelines, highlighting the importance of timely communication within government procurement processes. Overall, it reflects the structured management of government RFPs and contracts, ensuring that all interested parties are adequately informed of modifications that affect bidding procedures.
    SF30_SPE2D224R00150002.PDF
    The document outlines an amendment to a solicitation, specifically for contract SPE2D224R0015. It notifies recipients that the submission deadline for the solicitation has been extended to February 28, 2025, at 3:00 PM EST. The amendment clarifies that aside from this date change, all terms and conditions of the existing contract remain unchanged. This document serves as a formal communication from the issuing office, and it emphasizes the importance of acknowledging receipt of this amendment. Failure to do so may result in the rejection of offers. The amendment signifies the government's intent to provide additional time for potential contractors to prepare their submissions, indicative of the ongoing federal contracting process. Overall, the structure of the document is systematic and adheres to standard federal contracting language, ensuring clarity for participants in the solicitation process.
    Telmisartan Solicitation - SPE2D2-24-R-0015 - Final.pdf
    The document outlines Solicitation No. SPE2D2-24-R-0015 issued by the Defense Logistics Agency for the procurement of pharmaceutical products, specifically Telmisartan Tablets in various dosages, to be delivered over multiple contract years. Key elements include submission instructions for electronic proposals via the Defense Logistics Agency Internet Bid Board System (DIBBS), and detailed provisions regarding contractor compliance and performance assessments. It emphasizes the necessity for a Subcontracting Plan for large businesses and mandates adherence to various Federal Acquisition Regulation (FAR) clauses regarding ethics, child labor, and subcontracting practices. Also addressed are prohibitions against certain telecommunications equipment associated with foreign adversaries, along with specific trade agreements and duty-free entry conditions for eligible products. The aim of this solicitation is to secure reliable pharmaceutical supply while ensuring compliance with federal regulations and maintaining integrity in government contracting processes. This reflects a broader objective to streamline procurement in alignment with government standards and to foster accountability in contractor performance.
    Lifecycle
    Title
    Type
    Telmisartan Tablets
    Currently viewing
    Solicitation
    Similar Opportunities
    Dimethyl Fumarate DR Presolicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Lansoprazole Capsules
    Buyer not available
    The Defense Logistics Agency (DLA) is soliciting offers for the procurement of Lansoprazole DR 30MG capsules, a pharmaceutical product essential for treating various gastrointestinal conditions. This solicitation outlines the requirements for contractors to submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS), emphasizing compliance with Federal Acquisition Regulation (FAR) clauses and ethical business practices. The procurement is critical for maintaining the supply of necessary medications to support military personnel, ensuring adherence to stringent quality and legal standards. Interested contractors should direct inquiries to Jeremy Brown at jeremy.brown@dla.mil or Jason Wray at Jason.wray@dla.mil, with submissions due by the specified deadline in the solicitation document.
    Valsartan
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.
    Pantoprazole DR Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    Rabeprazole Sodium Delayed Release Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    Metformin HCL
    Buyer not available
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    DLA Hospital Supply TLS Sources Sought
    Buyer not available
    The Defense Logistics Agency (DLA) is conducting a market research survey to identify potential vendors for its Tailored Logistic Support (TLS) initiative, which focuses on acquiring hospital supply equipment and services for military and federally funded medical facilities. The initiative aims to enhance logistics support for medical professionals, requiring comprehensive supply chain capabilities, including shipping, inventory management, and transportation visibility. The anticipated contract, which may involve three to five Fixed Price Indefinite Quantity/Indefinite Delivery contracts with a cumulative maximum value of $400 million over five years, is set to last one year with four optional extensions. Interested vendors must submit a Capability Statement detailing their qualifications and capabilities, including email and Electronic Data Interchange (EDI) capabilities, by March 7, 2025. For further inquiries, vendors can contact Yasmeen Turner at yasmeen.turner@dla.mil or Zahkiyah Taylor at Zahkiyah.Taylor@dla.mil.
    Famotidine
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
    Rizatriptan Benzoate
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rizatriptan Benzoate tablets. The contract will establish a national supply source to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The solicitation will be posted on the DLA Bid Board System and SAM.gov. Interested parties should contact Keith Ryales for any questions/comments. The projected solicitation date is June 2022.
    Repaglinide
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Repaglinide Tablets. The contract will establish a national supply source for the purchase of Repaglinide 0.5MG, 1MG, and 2MG in 100 count bottles. This acquisition will be unrestricted and fully competitive. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items listed in the schedule will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. Interested parties should contact Phyllis Daraio for any questions/comments. The projected solicitation date is September 2020.